Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 AUD | +7.14% | +3.45% | -25.00% |
Apr. 11 | Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% | MT |
Mar. 18 | Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.61 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.00% | 57.62M | - | ||
+42.87% | 54.04B | B- | ||
+43.57% | 41.96B | A | ||
-1.16% | 41.92B | B | ||
-7.59% | 28.35B | C | ||
+11.95% | 26.35B | B- | ||
-22.02% | 19B | B | ||
+7.58% | 13B | B+ | ||
+28.86% | 12.28B | C+ | ||
+25.91% | 12.19B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BTH Stock
- Ratings Bigtincan Holdings Limited